Braincapture

BrainCapture operates at the intersection of medical devices, health diagnostics, and digital health, with a narrower focus than general remote-care platforms. Its differentiation is workflow-oriented: BC-1 combines portable EEG hardware, a Bluetooth-connected electrode cap, a mobile application for guided data collection, and a centralized cloud environment where remote experts can interpret and collaborate on results. This model targets hospitals, outpatient clinics, neurology departments, and acute-care settings that may not have EEG specialists immediately available. The company’s stated value proposition is therefore less about replacing specialist interpretation than about extending access to it and moving acquisition closer to the patient. BrainCapture’s competitive position is consequently best characterized as an early-stage, point-of-care EEG specialist. Its 2026 MedTech Innovator Asia Pacific Top 20 selection supports visibility in medtech, while its small employee base and limited disclosed financing indicate a much earlier scale profile than established diagnostic-device manufacturers.

BrainCapture’s trajectory shows a progression from company formation in 2019 toward product development, intellectual-property creation, and early medtech ecosystem validation. The European Innovation Council awarded the company €2,078,429, equivalent to $2,401,420, on Oct 6, 2021. A subsequent venture round led by Verge HealthTech Fund was announced on Sep 3, 2024, although its amount remains undisclosed. The product roadmap is represented by BC-1, a portable EEG device designed for point-of-care acquisition by non-specialists, supported by mobile and cloud software. A patent publication on Dec 20, 2023 covering EEG capture and a related electronic device indicates continued technical development. On May 19, 2026, BrainCapture was selected for MedTech Innovator Asia Pacific’s top-20 accelerator cohort from more than 680 applicants, marking a meaningful visibility and network milestone. Growth evidence remains incomplete: the company is listed in the 1–10 employee range, only two current featured positions are identified, and there is no hiring news or disclosed revenue. The pattern supports an early commercialization or scale-up phase rather than demonstrated mass-market expansion.